| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/22/2004 | US20040013721 Overcoated fluorescein particles |
| 01/22/2004 | US20040013720 Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| 01/22/2004 | US20040013718 Three-dimensional body; antiinflammatory agents, autoimmune diseases; in situ response; side effect reduction |
| 01/22/2004 | US20040013716 Sustained release of drug antagonist; analgesic reservoir, barrier layer |
| 01/22/2004 | US20040013708 Mixture containing emulsifiers, proteins and lipophilic starch; food processing |
| 01/22/2004 | US20040013706 Stress and radiation resistance; antiallergens; antiinflammatory agents |
| 01/22/2004 | US20040013704 Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
| 01/22/2004 | US20040013699 Antiprotozoa agents; swine; veterinary medicine |
| 01/22/2004 | US20040013697 Self-emulsifying active substance formulation and use of this formulation |
| 01/22/2004 | US20040013696 Topical applying |
| 01/22/2004 | US20040013695 Vaccines; mixture of excipients and antigens; water insoluble antacid as adjuvant; high speed dissolving |
| 01/22/2004 | US20040013693 Liquid pharmaceutical composition |
| 01/22/2004 | US20040013691 Immunotoxin as a therapeutic agent and uses thereof |
| 01/22/2004 | US20040013689 Prevention, therapy infectious diseases; insertion of nucleic acids into target cells |
| 01/22/2004 | US20040013687 Complexing Clostridium botulinum; translocation; induction immunology response |
| 01/22/2004 | US20040013680 Neurotoxic oligomers |
| 01/22/2004 | US20040013675 In situ detection of tumors; diagnosis of epilepsy, Alzheimer's disease, brain disorders |
| 01/22/2004 | US20040013667 Treatment with anti-ErbB2 antibodies |
| 01/22/2004 | US20040013662 Microbubble compositions and methods for oligonucleotide delivery |
| 01/22/2004 | US20040013645 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 01/22/2004 | US20040013644 Interferon beta-like molecules |
| 01/22/2004 | US20040013640 Antitumor agents; rheumatic agents; antiarthritic agents; tissue factor protein binding to antibody |
| 01/22/2004 | US20040013639 Injecting radiopaque material together with hydrogel having various visible dyes into the milk ducts for mapping and identifying |
| 01/22/2004 | US20040013637 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 01/22/2004 | US20040013636 Topical polymeric antimicrobial emulsion |
| 01/22/2004 | US20040013629 Spray on bandage and drug delivery system |
| 01/22/2004 | US20040013626 Controlled functionalizing of a biodegradable polymer by covalent grafting with a polysaccharide; vectors |
| 01/22/2004 | US20040013621 Transdermal delivery of antiemetics |
| 01/22/2004 | US20040013620 Antiparkinson agent, dermal penetration enhancer of a safe skin-tolerant sunscreen ester and a volatile liquid |
| 01/22/2004 | US20040013607 Conjugated to Y-90 through aminohexyl diethylenetriaminepentaacetic acid chelating agent |
| 01/22/2004 | DE10230875A1 Tubulysin-Biokonjugate Tubulysin bioconjugates |
| 01/22/2004 | DE10230769A1 Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren New pharmaceutical compositions based on new anticholinergics and PDE IV inhibitors |
| 01/22/2004 | DE10230751A1 Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern New pharmaceutical compositions based on new anticholinergics and EGFR kinase inhibitors |
| 01/22/2004 | DE10230750A1 Neue Arzneimittelkompositionen auf der Basis neuer Anticholonergika und NK1-Rezeptor-Antagonisten New pharmaceutical compositions based on new Anticholonergika and NK1 receptor antagonists |
| 01/22/2004 | DE10228680A1 Grundlage für transdermale Formulierungen (PTF) Basis for transdermal formulations (PTF) |
| 01/22/2004 | CA2782498A1 Tablet composition containing kampo medicinal extract and its manufacturing process |
| 01/22/2004 | CA2532324A1 Microbubble compositions, and methods for preparing and using same |
| 01/22/2004 | CA2492649A1 Therapies for renal failure using interferon-.beta. |
| 01/22/2004 | CA2492488A1 Liquid dosage compositions of stable nanoparticulate active agents |
| 01/22/2004 | CA2492485A1 Stable pharmaceutical composition comprising erythropoietin |
| 01/22/2004 | CA2492475A1 Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
| 01/22/2004 | CA2492297A1 Steroid conjugates, preparation thereof and the use thereof |
| 01/22/2004 | CA2492143A1 Methods and compositions for preventing oxidative degradation of proteins |
| 01/22/2004 | CA2492029A1 Transdermal botulinum toxin compositions |
| 01/22/2004 | CA2491661A1 The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| 01/22/2004 | CA2490976A1 Poly-gamma-glutamate having ultra high molecular weight and method for using the same |
| 01/21/2004 | EP1382687A1 Process for producing isomaltose and use thereof |
| 01/21/2004 | EP1382628A1 Biodegradable phase separated segmented/block co-polyesters |
| 01/21/2004 | EP1382352A1 Bisacyloxypropylcystein conjugates and the use thereof |
| 01/21/2004 | EP1382346A1 Conditioned medium and diffusible biological product produced by incubating entrapped cells |
| 01/21/2004 | EP1382337A1 Novel formulation containing paroxetine |
| 01/21/2004 | EP1382332A1 Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent |
| 01/21/2004 | EP1382331A1 A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids |
| 01/21/2004 | EP1382330A1 Aqueous-Based pharmaceutical composition |
| 01/21/2004 | EP1382263A2 Use of calcium in acidic oral compositions for the reduction of tooth erosion caused by acid |
| 01/21/2004 | EP1381611A1 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 01/21/2004 | EP1381432A2 Hsa-free formulations of interferon-beta |
| 01/21/2004 | EP1381397A2 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 01/21/2004 | EP1381394A2 Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming |
| 01/21/2004 | EP1381393A1 Microparticle protection of therapeutic agents |
| 01/21/2004 | EP1381391A1 Vaccines including as an adjuvant type 1 ifn and processes related thereto |
| 01/21/2004 | EP1381390A2 Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen |
| 01/21/2004 | EP1381385A1 Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability |
| 01/21/2004 | EP1381382A2 Methods and compositions for the treatment of diseases of the eye |
| 01/21/2004 | EP1381381A1 Patch for transcutaneous immunization |
| 01/21/2004 | EP1381377A2 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 01/21/2004 | EP1381376A2 In vivo use of water absorbent polymers |
| 01/21/2004 | EP1381374A1 Veterinary compositions comprising avermectin-oxime derivatives and praziquantel |
| 01/21/2004 | EP1381367A1 Aripiprazole oral solution |
| 01/21/2004 | EP1381358A1 Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp |
| 01/21/2004 | EP1381352A1 Transdermal patch for administering fentanyl |
| 01/21/2004 | EP1381346A2 Aerosol compositions containing formoterol for delivery to the lungs via nebulization |
| 01/21/2004 | EP1381344A2 Novel vaccine |
| 01/21/2004 | EP1169023B1 Process for the prepartation of SOLUBILIZING AIDS IN POWDER FORM FOR SOLID PHARMACEUTICAL PRESENTATION FORMS |
| 01/21/2004 | EP1150660B1 Pharmaceutical effervescent formulation containing metamizol |
| 01/21/2004 | EP1128826B1 Chromone enteric release formulation |
| 01/21/2004 | EP0999846B1 Phosphatidic acid-based immune modulator composition |
| 01/21/2004 | EP0944397B1 Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances |
| 01/21/2004 | EP0792164B1 Composition, device, and method for enhanced electrotransport agent delivery |
| 01/21/2004 | CN1469882A Esters |
| 01/21/2004 | CN1469872A A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidine-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b] thiophene hydrochloride |
| 01/21/2004 | CN1469868A Use of triazinetrione sulfones for combating coccidiosis |
| 01/21/2004 | CN1469759A Implants with a phosphazene-containing coating |
| 01/21/2004 | CN1469748A Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 01/21/2004 | CN1469744A Pharmaceutical compositions containing oxapenem-3-carboxylic acids |
| 01/21/2004 | CN1469742A Treatment and prophylaxis of diseases and infections of pigs and poultry with aivlosin |
| 01/21/2004 | CN1469738A Soft capsules comprising a starch mixture having reduced branching degree |
| 01/21/2004 | CN1469736A Use of a porous carrier |
| 01/21/2004 | CN1469735A Liposomal formulation of mitoxantrone |
| 01/21/2004 | CN1469734A Pharmaceutical form of administration for peptides, method for its production and use |
| 01/21/2004 | CN1469733A Method for producing powdery formulations |
| 01/21/2004 | CN1469707A Improved solid pharmaceutical dosage formulation of hydrophobic drugs |
| 01/21/2004 | CN1468867A Soluble high branched glucose polymer and its producing process |
| 01/21/2004 | CN1468599A Prepn for local treatment of tumor and chemotherapy of lymph and its prepn process |
| 01/21/2004 | CN1468594A Composition containing at least one oxidative sensitive hydrophilic active ingredient through at least one maleic anhydride copolymer stabilization |
| 01/21/2004 | CN1135104C Local anesthetic for external use |
| 01/21/2004 | CN1135103C Controlled release drugs delivered through sublingual or buccal administration |
| 01/20/2004 | US6680390 Sunscreen agents |
| 01/20/2004 | US6680372 Antibodies specific for growth differentiation factor-7 |
| 01/20/2004 | US6680301 For transferring dna and/or rna, such as genes, to cells by photochemically inducing the disruption of endosomes and lysosomes |